These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 4892933)

  • 1. [Developement of serum and urine concentrations of rifampicin during treatment].
    Pechère JC; Tancrède C
    Pathol Biol (Paris); 1969 Feb; 17(3):155-8. PubMed ID: 4892933
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum and urine concentrations of rifampicin administered by intravenous infusion in man.
    Acocella G; Bonollo L; Mainardi M; Margaroli P; Tenconi LT
    Arzneimittelforschung; 1977; 27(6):1221-6. PubMed ID: 578447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary excretion of rifampicin and its metabolites as an index of rifampicin blood levels.
    Wardell WM; McQueen EG
    N Z Med J; 1970 Dec; 72(463):393-6. PubMed ID: 5278257
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma and saliva concentrations of rifampicin in man after oral administration.
    Orisakwe OE; Ofoefule SI
    Tokai J Exp Clin Med; 1996 Feb; 21(1):45-9. PubMed ID: 9239804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rifampicin levels in blood, urine and kidney tissue in patients with renal tuberculosis].
    Mochalova TP; Kanevskaia SS; Danilova NK
    Antibiotiki; 1973 Feb; 18(2):178-80. PubMed ID: 4776397
    [No Abstract]   [Full Text] [Related]  

  • 6. Microbiological assay versus spectrophotometry for determination of rifampicin in urine.
    George J; Bhatia VN; Balakrishnan S
    Indian J Lepr; 1988 Jan; 60(1):47-52. PubMed ID: 3060546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local diffusibility of rifampicin in tuberculous lesions of bone and joint.
    Popescu E; Algeorge G; Paunescu E; Stoinescu M; Rudescu D
    Respiration; 1971; 28():Suppl:44-51. PubMed ID: 5150795
    [No Abstract]   [Full Text] [Related]  

  • 8. Proceedings: Kinetics of rifampicin and desacetyl-rifampicin in plasma, bile, and urine in humans and the effect of repeated administrations.
    Acocella G; Segre G
    Acta Pharm Suec; 1974 Dec; 11(6):657-8. PubMed ID: 1136808
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravenous use of rifampicin.
    Nilsson BS; Boman G
    Eur J Respir Dis; 1981 Jun; 62(3):212-4. PubMed ID: 7308336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of rifampicin serum concentrations in men, following drug administration before or after breakfast.
    Hussels H
    Acta Tuberc Pneumol Belg; 1969; 60(3):270-5. PubMed ID: 5371664
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S284-5. PubMed ID: 10593705
    [No Abstract]   [Full Text] [Related]  

  • 12. [Rifampicin and its clinical use].
    Fafrowicz B
    Wiad Lek; 1971 Jul; 24(3):233-8. PubMed ID: 4926926
    [No Abstract]   [Full Text] [Related]  

  • 13. Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one week.
    Acocella G; Mattiussi R; Segre G
    Pharmacol Res Commun; 1978 Mar; 10(3):271-88. PubMed ID: 684036
    [No Abstract]   [Full Text] [Related]  

  • 14. The Australian rifampicin trial.
    Proust AJ
    Med J Aust; 1971 Jul; 2(2):85-94. PubMed ID: 4999365
    [No Abstract]   [Full Text] [Related]  

  • 15. Rifampicin.
    Murdoch JM; Speirs CF; Wright N; Wallace ET
    Lancet; 1969 May; 1(7605):1094. PubMed ID: 4181749
    [No Abstract]   [Full Text] [Related]  

  • 16. [Urinary excretion of rifampicin in kidney failure when administered alone or together with isoniazid].
    Titarenko OT; Vakhmistrova TI; Perova TL
    Antibiotiki; 1983 Sep; 28(9):698-702. PubMed ID: 6638984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum rifampicin levels during low doses (300 mg per day)].
    Rautlin de la Roy Y DE; Patte F; Morichau-Beauchant G
    Rev Tuberc Pneumol (Paris); 1971; 35(3):342-50. PubMed ID: 4998870
    [No Abstract]   [Full Text] [Related]  

  • 19. Rifampicin, a general review.
    Binda G; Domenichini E; Gottardi A; Orlandi B; Ortelli E; Pacini B; Fowst G
    Arzneimittelforschung; 1971 Dec; 21(12):1907-77. PubMed ID: 4945790
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
    Panchagnula R; Singh I; Kaur KJ; Kaul CL
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):625-8. PubMed ID: 10669909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.